Meet Service Providers with ADC (Antibody-Drug Conjugate) Expertise


The excitement around ADCs for treating cancer stems from the realization that traditional, small-molecule cytotoxic drugs and radiation are still some of the most potent anticancer agents, and that targeting them by tethering them to antibodies might bypass some of the side effects. The recent founding investment by Johnson & Johnson of the ADC-focused startup, […]

Read More…